Viome, a biotech company that analyzes the human microbiome, has raised a $25 million Series D to launch its diagnostics division, CEO Naveen Jain tells Axios exclusively.
Why it matters: Only 8% of Americans are estimated to undergo routine preventative screenings, a figure that could improve with with at-home testing.
